Stockholm - Delayed Quote SEK

Devyser Diagnostics AB (publ) (DVYSR.ST)

Compare
129.50
+1.00
+(0.78%)
At close: January 31 at 5:24:53 PM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Fredrik Dahl CEO & Director 200k -- 1977
Ms. Sabina Berlin Chief Financial Officer -- -- 1983
Mr. Michael Uhlin Ph.D. Chief Scientific Officer -- -- 1978
Ms. Camilla Wiberg Chief Human Resource Officer -- -- 1979
Mr. Theis Kipling Chief Commercial Officer -- -- 1982
Mr. John Murad VP & GM of Devyser US -- -- --

Devyser Diagnostics AB (publ)

InstrumentvAegen 19
Hägersten, 126 53
Sweden
46 8 56 21 58 50 https://devyser.com
Sector: 
Healthcare
Full Time Employees: 
119

Description

Devyser Diagnostics AB (publ) develops, manufactures, and sells diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up. The company also provides software programs for data processing and analysis, as well as interpretation of test results; and Amplicon Suite and Advyser software programs to screen markers and follow up samples for the same patient. Devyser Diagnostics AB (publ) was incorporated in 2004 and is headquartered in Hägersten, Sweden.

Corporate Governance

Devyser Diagnostics AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 13, 2025 at 6:30 AM UTC

Devyser Diagnostics AB (publ) Earnings Date

Recent Events

November 25, 2024 at 12:30 PM UTC

Capital Markets Day

October 30, 2024 at 8:00 AM UTC

Q3 2024 Earnings Call

Related Tickers